Author: David Browne
-
Optimisation of a Portfolio of Established Brands
by
Challenge: The problem with portfolios is that they are looked at as one and this does not reflect the reality. This portfolio was 15 medicines, the majority of which were in one therapy area. As a whole the portfolio was losing volumes year on year, losing revenue and losing margin to an even greater degree…
-
Category H introduction …. the end of branded generics in the UK?
by
Category H introduction has been announced although detail is lacking. It will undoubtedly affect branded generics and this article gives an outline as to how and why.
-
Repurposed molecule > Go-to-market & launch strategy > Operational structure options
by
Challenge: This Germany headquartered developer wanted to enter the UK market with a repurposed molecule (new form, new indication). They needed confirmation of the likely pricing window and volume forecast. They wanted advice on go-to-market and launch strategy and also the operational structure options to succeed in this less familiar, non-EU market.
-
Re-positioning an established “Alternative Brand” (branded-generic)
by
Challenge: In the UK, NHS advice is to prescribe some products (including drug / device combinations) by brand name when generics exist, so that patient continuity is ensured. With the launch of a new competitor branded-generic, this company’s alternative brand’s positioning was no longer compelling or even valid. We supported the UK affiliate to reposition…
-
Insight: the bedrock of any good plan … but KISS!
by
Insight is the bedrock of any good plan or business decision. Make sure you KISS (Keep It Simple Stupid) and focus on the data that matters, displaying it simply and graphically.
-
Established molecules – more than “just” generics?
by
A frequent response to hearing the words “established molecules” is “so you mean generics, right?” Well yes, and no! There is more to it than “just generics” and in fact this is an exciting and profitable area of pharma and one we love to work on here at Hawk Pharma Consulting.
-
Business Development (BD) – Target Product Profile (TPP) realignment to optimise success
by
Challenge: The challenges in the BD process include finding the finding the assets that you want, convincing the potential partner that you are right for their asset and making an appropriate offer that is accepted by both the partner’s, and your company’s, Board. To streamline efforts and optimise in-license success it was imperative for this…
-
OMD: Fractional, interim support from Hawk Pharma Consulting
by
We are delighted to add OMD, Our Marketing Department, to the offering from Hawk Pharma Consulting. Our fractional, interim marketing resource offering will help you turn plans into execution of materials, programs and tactics. For more detail: Our Marketing Department – Hawk Pharma Consulting
-
Testimonial – the Hawk Pharma Consulting difference!
by
“As Managing Director & Consultancy Lead it is hugely rewarding when a client takes time out of their busy day to write a testimonial – it means a lot to the team and me”, said David Browne. “Personally I enjoyed working with this Country Manager of the UK affiliate of an Asia-based Biotech Multinational. They…
-
Environmental Footprint part 2 – Getting started!
by
In most parts of Europe the pressure is on with regard to carbon and moving towards net zero. This is no longer a “nice-to-do” thing that creates positive PR – it is now a “must-do”. An example is the UK NHS insistence on seeing a company’s carbon reduction plan in order to be considered as…
-
Environmental Footprint & Sustainability – explained simply!
by
The NHS has the target of being carbon net zero by 2040 and, as the customer of all UK-based pharma companies, the industry must respond to that target to align with our customer in order to be considered a supplier for the future. There is another side to this: we do have breakthroughs in orphan…
-
Environmental Focus & Sustainability – Building a compelling & compliant strategy & communication
by
Challenge: All companies feel compelled to talk about environmental focus and there is a danger that this can seem like “green-washing”. The NHS has a goal of becoming carbon net zero by 2040 and it has a focus on respiratory inhalers and gaseous anaesthetics as major contributor to the issue. We needed to develop a…
-
Feasibility of Nordic launch > Strategies for launch
by
Challenge: The Nordic affiliate of a European pharma company needed advice on the feasibility of launching two related branded generics (or alternative brands) into the four major Nordic markets. Assuming there was opportunity they sought strategic advice on how to launch most effectively.
-
Education and Strategic Marketing
by
4th June 2024 saw the EMIG HR group meet and our Managing Director & Lead Consultant, David Browne, present having been invited by the Chair of the Group, Dr Jim Golby. We love our marketing, commercial and go-to-market projects but we are always open to supporting and educating others. We did a session in a…
-
New product feasibility, forecasting & P&L > go-to-market & launch strategy
by
Challenge: A pharma company headquartered in Asia Pacific wanted to assess feasibility, go-to-market and launch strategy for a brand that would be the first licensed medicine to treat an increasingly recognised condition in women’s health in the UK. This would assist their decision making and BD process.
-
New product launch > Portfolio strategy and positioning
by
Challenge: The UK affiliate of an international pharma company was launching two new brands and, in doing so, it was creating a portfolio in this therapy area. The new portfolio needed a strategy, positioning and messaging. New and existing brands needed their own story within the overall portfolio communication.
